-
摘要: 在过去的几十年里,血栓性血小板减少性紫癜（thrombotic thrombocytopenic purpura,TTP）[1],以及血管性血友病因子裂解酶（ADAMTS13）被人们逐步深度关注[2]。基于对TTP分子机制的深入研究,并且得益于George教授所引领的TTP注册登记库的建立[3],我们对这种致命性血栓疾病的研究取得了重大进展,从而使得该病的诊断和治疗管理都得到了显著改善。为了加深国内血液学同行对该病的理解,提高TTP在我国的治疗效果,我们总结了该病近年来的诊治进展,诣在抛砖引玉,为TTP治疗提供一些参考。
-
Key words:
- thrombotic thrombocytopenic purpura /
- diagnosis /
- treatment
-
-
[1] Brain MC.An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries(Moschcowitz 1925)[J].Thromb Haemost,1978,40(1):9-10.
[2] Kremer Hovinga JA,Vesely SK,Terrell DR,et al.Survival and relapse in patients with thrombotic thrombocytopenic purpura[J].Blood,2010,115(8):1500-1511.
[3] George JN,Vesely SK,Terrell DR,et al.The Oklahoma Thrombotic Thrombocytopenic Purpura-haemolytic Uraemic Syndrome Registry.A model for clinical research,education and patient care[J].Hamostaseologie,2013,33(2):105-112.
[4] Moake JL,Rudy CK,Troll JH,et al.Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura[J].N Engl J Med,1982,307(23):1432-1435.
[5] Asada Y,Sumiyoshi A,Hayashi T,et al.Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura,with special reference to factor VIII related antigen[J].Thromb Res,1985,38(5):469-479.
[6] Rock GA,Shumak KH,Buskard NA,et al.Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.Canadian Apheresis Study Group[J].N Engl J Med,1991,325(6):393-397.
[7] Furlan M,Robles R,Lammle B.Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis[J].Blood,1996,87(10):4223-4234.
[8] Furlan M,Robles R,Galbusera M,et al.von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome[J].N Engl J Med,1998,339(22):1578-1584.
[9] Tsai HM,Lian EC.Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura[J].N Engl J Med,1998,339(22):1585-1594.
[10] Zheng X,Chung D,Takayama TK,et al.Structure of von Willebrand factor-cleaving protease(ADAMTS13),a metalloprotease involved in thrombotic thrombocytopenic purpura[J].J Biol Chem,2001,276(44):41059-41063.
[11] Sadler JE.Pathophysiology of thrombotic thrombocytopenic purpura[J].Blood,2017,130(10):1181-1188.
[12] George JN,Nester CM.Syndromes of thrombotic microangiopathy[J].N Engl J Med,2014,371(7):654-666.
[13] Fujimura Y,Matsumoto M,Isonishi A,et al.Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan[J].J Thromb Haemost,2011,9(Suppl 1):283-301.
[14] Moake JL.Thrombotic microangiopathies[J].N Engl J Med,2002,347(8):589-600.
[15] Mariotte E,Azoulay E,Galicier L,et al.Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency(thrombotic thrombocytopenic purpura):a cross-sectional analysis of the French national registry for thrombotic microangiopathy[J].Lancet Haematol,2016,3(5):e237-e245.
[16] Noris M,Remuzzi G.Atypical hemolytic-uremic syndrome[J].N Engl J Med,2009,361(17):1676-1687.
[17] Sadler JE.What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura[J].Hematology Am Soc Hematol Educ Program,2015,2015(1):631-636.
[18] 中华医学会血液学分会血栓与止血学组.血栓性血小板减少性紫癜诊断与治疗中国专家共识(2012年版)[J].中华血液学杂志,2012,33(11):980-981.
[19] Sarode R,Bandarenko N,Brecher ME,et al.Thrombotic thrombocytopenic purpura:2012 American Society for Apheresis(ASFA)consensus conference on classification,diagnosis,management,and future research[J].J Clin Apher 2014,29(3):148-167.
[20] Scully M,Hunt BJ,Benjamin S,et al.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies[J].Br J Haematol,2012,158(3):323-335.
[21] Froissart A,Buffet M,Veyradier A,et al.Efficacy and safety of first-line rituximab in severe,acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange.Experience of the French Thrombotic Microangiopathies Reference Center[J].Crit Care Med,2012,40(1):104-111.
[22] Balduini CL,Gugliotta L,Luppi M,et al.High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura:a randomized study[J].Ann Hematol,2010,89(6):591-596.
[23] Scully M,McDonald V,Cavenagh J,et al.A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura[J].Blood,2011,118(7):1746-1753.
[24] Chen J,Reheman A,Gushiken FC,et al.N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice[J].J Clin Invest,2011,121(2):593-603.
[25] Rottenstreich A,Hochberg-Klein S,Rund D,et al.The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura[J].J Thromb Thrombolysis,2016,41(4):678-683.
[26] Shortt J,Oh DH,Opat SS.ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura[J].N Engl J Med,2013,368(1):90-92.
[27] Plaimauer B,Kremer Hovinga JA,Juno C,et al.Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies[J].J Thromb Haemost,2011,9(5):936-944.
[28] Schiviz A,Wuersch K,Piskernik C,et al.A new mouse model mimicking thrombotic thrombocytopenic purpura:correction of symptoms by recombinant human ADAMTS13[J].Blood,2012,119(25):6128-6135.
[29] Peyvandi F,Scully M,Kremer Hovinga JA,et al.Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura[J].N Engl J Med,2016,374(6):511-522.
-
计量
- 文章访问数: 511
- PDF下载数: 581
- 施引文献: 0
下载: